Genetic variation in drug transporters in ethnic populations (Clinical Pharmacology and Therapeutics (2008) 84, (412-416) DOI: 10.1038/clpt.2008.98);Genetic variation in drug transporters in ethnic populations

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 3, 2008, Pages 412-416

  Cropp, C D ^a   Yee, S W ^a   Giacomini, K M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALLOPURINOL; AMANTADINE; BREAST CANCER RESISTANCE PROTEIN; BUMETANIDE; CARNITINE; CARRIER PROTEIN; CEFOTAXIME; CIMETIDINE; CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; GABAPENTIN; GANCICLOVIR; KETOPROFEN; METFORMIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 6; OCTAMER TRANSCRIPTION FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 2; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER 4; OXALIPLATIN; OXIPURINOL; TENOFOVIR; UNINDEXED DRUG;

AFRICAN AMERICAN; ALLELE; ASIAN; CYP2E1 GENE; CYPE1A1 GENE; DRUG DISPOSITION; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSPORT; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; GENE; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; METABOLIC RATE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

EID: 49949089862     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.232     Document Type: Erratum

References (24)

1. Ingelman-Sundberg, M. Polymorphisms of cytochrome P450 and xenobiotic toxicity. Toxicology 181-182, 447-452 (2002).
2. Leabman, M.K. et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc. Natl. Acad. Sci. USA 100, 5896-5901 (2003).
3. Badagnani, I. et al. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J. Pharmacol. Exp. Ther. 318, 521-529 (2006).
4. Urban, T.J. et al. Functional genomics of membrane transporters in human populations. Genome Res. 16, 223-230 (2006).
5. Ho, R.H. et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet. Genomics 17, 647-656 (2007).
6. Zhang, W. et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta. 373, 99-103 (2006).
7. Jonker, J.W. & Schinkel, A.H. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther. 308, 2-9 (2004).
8. Koepsell, H., Lips, K. & Volk, C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 24, 1227-1251 (2007).
9. Rizwan, A.N. & Burckhardt, G. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm. Res. 24, 450-470 (2007).
10. Sekine, T., Miyazaki, H. & Endou, H. Molecular physiology of renal organic anion transporters. Am. J. Physiol. Renal Physiol. 290, F251-F261 (2006).
11. Enomoto, A. et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417, 447-452 (2002).
12. Iwanga, T., Kobayashi, D., Hirayama, M., Maeda, T. & Tamai, I. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by uricosuric agent, benzbromarone. Drug Metab. Dispos. 33, 1791-1795 (2005).
13. Niemi, M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8, 787-802 (2007).
14. Tirona, R.G. & Kim, R.B. Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv. Drug Deliv. Rev. 54, 1343-1352 (2002).
15. Ito, K., Suzuki, H., Horie, T. & Sugiyama, Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res. 22, 1559-1577 (2005).
16. Grube, M. et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin. Pharmacol. Ther. 80, 607-620 (2006).
17. Otsuka, M., Matsumoto, T., Morimoto, R., Arioka, S., Omote, H. & Moriyama, Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. USA 102, 17923-17928 (2005).
18. Tanihara, Y., Masuda, S., Sato, T., Katsura, T., Ogawa, O. & Inui, K.-I. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/ H+-organic cation antiporters. Biochem. Pharmacol. 74, 359-371 (2007).
19. Masuda, S. et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol. 17, 2127-2135 (2006).
20. Cascorbi, I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 112, 457-473 (2006).
21. Huang, Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev. 26, 183-201 (2007).
22. Kerb, R., Hoffmeyer, S. & Brinkmann, U. ABC transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2, 51-64 (2001).
23. Lepper, E.R., Nooter, K., Verweij, J., Acharya, M.R., Figg, W.D. & Sparreboom, A. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 6, 115-138 (2005).
24. Stieger, B., Meier, Y. & Meier, P.J. The bile salt export pump. Pflugers Arch. 453, 611-620 (2007).